Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

BACKGROUND: A phase II trial of pasireotide was performed to assess its efficacy and safety in advanced or metastatic hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Patients with advanced HCC and Child–Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days. Primary endpoin...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Hepatocell Carcinoma
Main Authors: Feun, Lynn G, Wangpaichitr, Medhi, Li, Ying-Ying, Kwon, Deukwoo, Richman, Stephen P, Hosein, Peter J, Savaraj, Niramol
格式: Artigo
語言:Inglês
出版: Dove Medical Press 2018
主題:
Original Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5769585/
https://ncbi.nlm.nih.gov/pubmed/29392123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S153672
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍